Automate Your Wheel Strategy on LIVN
With Tiblio's Option Bot, you can configure your own wheel strategy including LIVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LIVN
- Rev/Share 23.9899
- Book/Share 20.5735
- PB 2.546
- Debt/Equity 0.4216
- CurrentRatio 1.289
- ROIC 0.116
- MktCap 2860004204.0
- FreeCF/Share 2.9701
- PFCF 17.6438
- PE -13.5282
- Debt/Assets 0.1889
- DivYield 0
- ROE -0.1766
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LIVN | Goldman | Buy | Neutral | -- | $55 | Oct. 1, 2025 |
| Upgrade | LIVN | Wolfe Research | Peer Perform | Outperform | -- | $60 | May 20, 2025 |
| Downgrade | LIVN | Wolfe Research | Outperform | Peer Perform | -- | -- | Feb. 26, 2025 |
| Initiation | LIVN | Goldman | -- | Buy | -- | $65 | Oct. 4, 2024 |
| Upgrade | LIVN | Robert W. Baird | Neutral | Outperform | $55 | $66 | Sept. 17, 2024 |
News
Should Value Investors Buy LivaNova (LIVN) Stock?
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
Published: August 22, 2025 by: Business Wire
Sentiment: Neutral
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business update during fireside chats at the two following September healthcare conferences in New York City: Baird 2025 Global Healthcare Conference on Tues., Sept. 9, from 3:45-4:15 p.m. EDT Morgan Stanley 23rd Annual Global Healthcare Conference on Wed., Sept.
Read More
LivaNova: The Sell-Off Is Excessive Here
Published: July 07, 2025 by: Seeking Alpha
Sentiment: Neutral
LivaNova offers strong medtech upside with market-leading positions in cardiac surgery and neuromodulation, but lacks a dividend yield. Recent results show double-digit organic growth, margin expansion, and a positive sales trajectory, especially in Cardiopulmonary. Valuation is attractive: at a discounted 17x P/E, I see 20%+ annual upside and limited downside risk at current prices.
Read More
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.
Read More
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.
Read More
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis as compared to the prior-year period First-quarter U.S. GAAP diluted loss per share of $6.01, impacted by recording SNIA.
Read More
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an A.
Read More
About LivaNova PLC (LIVN)
- IPO Date 2015-10-19
- Website https://www.livanova.com
- Industry Medical - Devices
- CEO Vladimir A. Makatsaria
- Employees 2900